# Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy

> **NCT00860093** · PHASE2 · TERMINATED · sponsor: **Mission Pharmacal** · enrollment: 135 (actual)

## Conditions studied

- Nephrolithiasis

## Interventions

- **OTHER:** placebo
- **DRUG:** MPC-5971

## Key facts

- **NCT ID:** NCT00860093
- **Lead sponsor:** Mission Pharmacal
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2010-11
- **Final completion:** 2010-12
- **Target enrollment:** 135 (ACTUAL)
- **Why stopped:** Sponsor Corporate Business Decision
- **Last updated:** 2019-03-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00860093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00860093, "Efficacy and Safety of Using MPC-5971 in Subjects Undergoing Shock Wave Lithotripsy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00860093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*